Closed‐loop insulin delivery is an emerging diabetes technology that has the potential to address the unmet clinical need for improved glucose control while reducing the burden of hypoglycaemia and self‐care in Type 1 diabetes 4. The gene discussed is INS; the disease is Hypoglycemia.